Paper Details

  1. Home
  2. Paper Details

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report.

Author: CuiXiaonan, FanBuqun, JiangKaiteng, LiQizheng, YangYudie, ZhangBin, ZhangChunxia, ZhangJie, ZhangXia

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Trifluridine/tipiracil (TAS-102) is a new drug for treating metastatic colorectal cancer (mCRC) that has shown promise as a third-line treatment option. In a case study, anlotinib combined with TAS-102 showed significant efficacy in a patient with refractory mCRC, providing a prolonged progression-free survival benefit of over 20 months. While further research is needed, this combination therapy appears to be a promising option for treating mCRC, particularly in patients who have failed first- and second-line therapies.
Paper Details　
Original Abstract of the Article :
Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748473/

データ提供：米国国立医学図書館（NLM）

Anlotinib Combined with TAS-102 for Metastatic Colon Cancer

This study explores the use of anlotinib combined with TAS-102 as a third-line treatment option for patients with metastatic colon cancer. It's like discovering a new oasis in a familiar desert – seeking innovative approaches to combat a challenging disease.

Promising Third-Line Treatment for Metastatic Colon Cancer

This research presents a case report of a patient with metastatic colon cancer who experienced significant benefit from the combination of anlotinib and TAS-102 as a third-line treatment. The patient achieved a prolonged progression-free survival of over 20 months with minimal adverse reactions. It’s a beacon of hope for those facing advanced disease, suggesting a potentially effective and well-tolerated treatment option.

Exploring New Treatment Regimens

The study's findings highlight the importance of continuous research and development in oncology, seeking new and effective treatment options for patients with advanced cancer. It emphasizes the need for clinical trials to further evaluate the efficacy and safety of this promising combination therapy. It’s a reminder that the desert of cancer research is vast and ever-evolving, and we must remain persistent in our search for better treatments.

Dr.Camel's Conclusion

This case report provides a compelling example of the potential benefits of anlotinib combined with TAS-102 as a third-line treatment for metastatic colon cancer. The study’s findings highlight the importance of continuous research and development in oncology, seeking new and effective treatment options for patients with advanced cancer. It’s a reminder that even in the face of challenging diseases, we must never stop exploring new horizons in healthcare, seeking innovative solutions to improve patient outcomes and quality of life.
Date :
  1. Date Completed n.d.
  2. Date Revised 2022-12-22
Further Info :

Pubmed ID

36531025

DOI: Digital Object Identifier

PMC9748473

Related Literature

Article Analysis
・Side Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.